1Gong MC,Latouche JB,Krause A,et al.Cancer patient T ceLLs geneticaLLy targeted to prostate-specific membrane antigen specificaLLy Lyse prostate cancer ceLLs and reLease cytokines in response to prostate-specific membrane antigen[J].NeopLasia,1999,1(2):123.
2BatLiwaLLa FM,Rufer N,Lansdorp PM,et al.OLigocLonaL expansions in the CD8+CD28-T ceLLs LargeLy expLain the shorter teLomeres detected in this subset:anaLysis by fLow FISH[J].Hum ImmunoL,2000,61(10):951.
3Gong M G, Latonche T B, Kranse A, et al. Cancer patient T cell genetically targeted toprostate - specific membrane antigen specifically lyse prostate cancer cells and release cytokines inrespanse to prostate - specific membrane antigen. Neoplasia, 1999,1:123
4Okazaki K, Nakayama Y, Shibon K, et al . Enhancement of metastatic activity of colon cancer as influenced by expression of cell surface antigens. Surg Res, 1998,78 : 78
5Nociari M M, Telford W, Russo C. Postthymic development of CD8^+ CD^28 ^- T cell ssubset: age - associated expansion and shift from memory to have phenotype. J Immunol, 1999,162 : 3327
6Onsrad M, Grahm I, Gaudemack G, et al. Lymphoid cell distribution as prognostic in carcinoma of the uterine cervix[ J ]. Acta Obstet Gynecol Scand, 1992,71 : 135.
7BatliwaUa FM, Ruler N, Lansdorp PM, et al. Oligoclonal expansions in the CD8( + )CD28( - ) T cells largely explain the shorter telomeres detected in this subset : analysis by flow FISH [ J ]. Hum Immttnol, 2000,61 (10) :951.
8Azuma M, Phillips JH, Lanier LL. CD28^- T lymphocytes. Antigenic and functional properties[ J]. J Immunol, 1993,150(4 ) : 1147.
9Ciubotariu R, Vasilescu R, Ho E, et al. Detection of T suppressor cells in patients with organ allografts [ J ]. Hum Immunol, 2001,62 ( 1 ) : 15.
10Arosa FA, Oliveira L, Porto G, et al. Anomalies of the CD8 ^+ T cell pool in haemochromatosis: HLA-A3-linked expansions of CD8^+ CD28^- T cells [J] .Clin Exp Immunol, 1997,107(3) :548.
3Kiniwa Y, Miyahara Y, Wang H Y, et al. CD8^+ Foxp3^+ regμLatory T cells mediate immunosuppression in prostate can eer[J]. Clin Cancer Res, 2007, 13(23): 6947.
4Cooper M.A, T.A. Fehniger, M.A. Caligiuri. The biology of human natural killer-cell subsets [ J ]. Trends Immunol, 2001, 22(11): 633.
6MASTELLER E L, CHUANG E, MULLEN A C, et al. Structural analysis of CTLA-4 function in vivo [J ]. J Immunol, 2000, 164(10): 5319-5327.
7ECK S C, TURKA L A. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4+ T ceils [J]. Cancer Immunol Immunother, 1999, 48(6): 336-341. i.
8ALVES N L, AROSA F A, VAN LIER R A. IL-21 sustains CD28 expression on IL-15-aetivated human naive CD8+ T cells[J].J Immunol, 2005, 175(2): 755-762.
9GODLOVE J, CHIU W K, WENG N P. Gene expression and generation of CD28-CD8 T cells mediated by interleukin 15[J].ExpGerontol, 2007, 42(5): 412-415.
10MARTiNEZ-ESCRIBANO J A, HERNANDEZ-CASELLES T, CAMPILLO J A, et al. Changes in the number of CDS0+, CD86+, and CD28+ peripheral blood lymphocytes have prognostic value in melanoma patients[J]. Hum Immunol, 2003, 64(8): 796-801.
